These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 35966763)
41. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
42. Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor. Treewattanawong W; Sitthiyotha T; Chunsrivirot S Sci Rep; 2023 Sep; 13(1):15476. PubMed ID: 37726329 [TBL] [Abstract][Full Text] [Related]
43. Molecular Dynamics Studies on the Structural Stability Prediction of SARS-CoV-2 Variants Including Multiple Mutants. Choi KE; Kim JM; Rhee JE; Park AK; Kim EJ; Yoo CK; Kang NS Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563345 [TBL] [Abstract][Full Text] [Related]
44. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis. Khater I; Nassar A Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832 [TBL] [Abstract][Full Text] [Related]
45. Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike - ACE2 complexes reveal distinct changes between both variants. Socher E; Heger L; Paulsen F; Zunke F; Arnold P Comput Struct Biotechnol J; 2022; 20():1168-1176. PubMed ID: 35251533 [TBL] [Abstract][Full Text] [Related]
46. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective. Ibrahim IM; Elfiky AA; Elgohary AM Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205 [TBL] [Abstract][Full Text] [Related]
47. Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape. Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV bioRxiv; 2021 Dec; ():. PubMed ID: 34494024 [TBL] [Abstract][Full Text] [Related]
48. Structure-based drug discovery to identify SARS-CoV2 spike protein-ACE2 interaction inhibitors. Kant R; Kaushik R; Chopra M; Saluja D J Biomol Struct Dyn; 2024 Jan; ():1-19. PubMed ID: 38174578 [TBL] [Abstract][Full Text] [Related]
49. In silico investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface. Ali N; Khan R; AlAsmari AF; Kumar V Process Biochem; 2022 Apr; 115():70-79. PubMed ID: 35194375 [TBL] [Abstract][Full Text] [Related]
50. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454 [TBL] [Abstract][Full Text] [Related]
51. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. Dehury B; Raina V; Misra N; Suar M J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417 [TBL] [Abstract][Full Text] [Related]
52. Unraveling the binding mechanisms of SARS-CoV-2 variants through molecular simulations. Ju SP; Yang YC; Chen HY Heliyon; 2024 Mar; 10(5):e27193. PubMed ID: 38495173 [TBL] [Abstract][Full Text] [Related]
53. Divergent mutations of Delta and Omicron variants: key players behind differential viral attributes across the COVID-19 waves. Panja A; Roy J; Mazumder A; Choudhury SM Virusdisease; 2023 May; 34(2):1-14. PubMed ID: 37363365 [TBL] [Abstract][Full Text] [Related]
54. Evaluating therapeutic potential of AYUSH-64 constituents against omicron variant of SARS-CoV-2 using ensemble docking and simulations. Jani V; Koulgi S; Uppuladinne MVN; Thrigulla SR; Gundeti M; Prasad GP; Kumar S; Narayanam S; Sonavane U; Joshi R Curr Res Struct Biol; 2024; 7():100151. PubMed ID: 38881558 [TBL] [Abstract][Full Text] [Related]
55. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
56. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. Chakraborty S Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568 [TBL] [Abstract][Full Text] [Related]
57. VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry. Ding S; Gong SY; Grover J; Mohammadi M; Chen Y; Vézina D; Beaudoin-Bussières G; Verma VT; Goyette G; Richard J; Yang D; Smith AB; Pazgier M; Côté M; Abrams C; Mothes W; Finzi A; Baron C bioRxiv; 2022 Feb; ():. PubMed ID: 35233570 [TBL] [Abstract][Full Text] [Related]
58. High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. Bhadane R; Salo-Ahen OMH Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359299 [TBL] [Abstract][Full Text] [Related]
59. Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding. Hoter A; Naim HY Front Mol Biosci; 2022; 9():893843. PubMed ID: 35677879 [TBL] [Abstract][Full Text] [Related]
60. Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y. Zhu Y; Zhou W; Niu Z; Sun J; Zhang Z; Li Q; Zheng Y; Wang C; Gao L; Sun Q Biol Direct; 2022 Jun; 17(1):14. PubMed ID: 35658928 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]